# Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

> **NCT07639138** · PHASE2 · RECRUITING · sponsor: **Shunda Du** · enrollment: 32 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Targeted Therapy
- **DRUG:** Immune Checkpoint Inhibitors

## Key facts

- **NCT ID:** NCT07639138
- **Lead sponsor:** Shunda Du
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-12
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639138, "Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07639138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*